New Launch20 Mar 2025, 10:36 pm
Piramal Critical Care and BrePco Receive MHRA Approval for Neoatricon in the UK
AI Summary
Piramal Critical Care (PCC) and BrePco Biopharma Limited have announced the receipt of Market Authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Neoatricon, a paediatric strength solution for infusion of Dopamine Hydrochloride. This approval marks a significant step for PCC as it expands into a new therapeutic area. Neoatricon is developed by BrePco and will be distributed by PCC in the EU, UK, and Norway. The new formulation ensures precise dosing, reduces the risk of under- or overdosing, and minimizes preparation time in neonatal and paediatric intensive care units, improving health outcomes for paediatric patients.
Key Highlights
- MHRA approval for Neoatricon, a paediatric strength solution for Dopamine Hydrochloride infusion
- Addresses the gap in approved formulations for neonates, infants, and children
- Ensures precise dosing and reduces the risk of under- or overdosing
- Minimizes preparation time in neonatal and paediatric intensive care units
- Significant step for Piramal Critical Care as it expands into a new therapeutic area